Active Biotech AB

Type: Company
Name: Active Biotech AB
Nationality: Sweden
Web Address: http://activebiotech.com/
Fact Sheet: Fact Sheet for Active Biotech AB
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or

- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS) who were treated ... [Published PR inside - Sep 23 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Teva and Active Biotech announce encouraging data from multiple sclerosis study

Teva Pharmaceutical Industries Ltd. and Active Biotech have announced encouraging follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis, or RRMS, who were treated with laquinimod in Phase II, ... [Published Individual.com - Sep 17 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Teva And Active Biotech Announce New Follow-up Data On Laquinimod - Quick Facts

Teva Pharmaceutical Industries Ltd. (TEVA: Quote) and Active Biotech announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis or RRMS who were treated with laquinimod in Phase II, ... [Published RTTNews.com - Sep 12 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Global Multiple Sclerosis Drugs Market 2014-2018 New Research Report

Dallas, TX -- ( ReleaseWire ) -- 08/25/2014 -- The report Global Multiple Sclerosis Drugs Market 2014-2018 says one of the emerging trends in the market is the introduction of disease-modifying drugs as a treatment option. Drugs such as Copaxone (Glatiramer ... [Published SBWire - Aug 25 2014]
First reported Aug 23 2014 - Updated Aug 23 2014 - 1 reports

Global Multiple Sclerosis Drugs Market : 2014-2018

Press ReleaseTechNavio Announces the Publication of its Research Report - Global Multiple Sclerosis Drugs Market 2014-2018TechNavio recognizes the following companies as the key players in the Global Multiple Sclerosis Drugs Market: Bayer AG, Biogen Idec ... [Published MarketResearch.com - Aug 23 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

The Launch of Five Immunomodulatory Therapies for Relapsing Forms of Multiple Sclerosis Will Contribute to 4 Percent Annual Growth of the Total Market from 2013 to 2023

BURLINGTON, Mass., Aug. 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, ... [Published PR Newswire: General Business - Aug 07 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 1 reports

Cantargia gears up with new CEO and substantial capital injection

Cantargia, a private biopharmaceutical company developing therapeutics for the treatment of leukemia, announces that Dr. Göran Forsberg will take over the CEO position Furthermore, the company has decided to issue new shares corresponding to 20 MSEK.Cantargia ... [Published CisionWire - English - Jun 17 2014]
First reported May 26 2014 - Updated May 26 2014 - 1 reports

EMA's CHMP rejects approval of multiple sclerosis drug Nerventra

European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rejected the development of Nerventra (Laquinimod) for the treatment of relapsing-remitting multiple sclerosis (RRMS) by Israel-based Teva Pharmaceutical and Swedish ... [Published PBR - News - May 26 2014]
First reported May 23 2014 - Updated May 23 2014 - 2 reports

Teva and Active Biotech to Continue with the Development of Nerventra® (Laquinimod) for Multiple Sclerosis Following Confirmation of CHMP Opinion

JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) announced today that the Committee for Medicinal Products for Human Use (CHMP) confirmed its January 23, 2014 opinion ... [Published Business Wire Science: Science News - May 23 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Active Biotech schedules AGM

Active Biotech AB will hold its annual general meeting at Elite Hotel Ideon, Scheelev$¤gen 27 in Lund, Sweden, on 15 May at 5 p.m.Story provided by StockMarketWire.com ... [Published TrustNet - Apr 14 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 2 reports

Annual Report 2013 Active Biotech AB publ

Active Biotech 's Annual Report 2013 (in Swedish) is now available for download at www.activebiotech.com . The English version will be available within short.Related Biotechnology, Pharmaceutical and Healthcare NewsThe Annual Report will only be digitally ... [Published BioPortfolio - Apr 07 2014]

More Content

All (39) | News (11) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (5) | Press Releases (17)
sort by: Date | Relevance
Teva Presents New Clinical Safety Data in RRMS ... [Published PR inside - Sep 23 2014]
Teva and Active Biotech announce encouraging da... [Published Individual.com - Sep 17 2014]
Teva And Active Biotech Announce New Follow-up ... [Published RTTNews.com - Sep 12 2014]
Teva Presents New Clinical Safety Data in RRMS ... [Published GlobeNewswire: Acquisitions News - Sep 12 2014]
Teva Presents New Clinical Safety Data in RRMS ... [Published Business Wire Health News - Sep 12 2014]
Global Multiple Sclerosis Drugs Market 2014-201... [Published SBWire - Aug 25 2014]
Global Multiple Sclerosis Drugs Market : 2014-2018 [Published MarketResearch.com - Aug 23 2014]
Active Biotech's partner Teva initiates a laqui... [Published GlobeNewswire: Advertising News - Aug 14 2014]
Active Biotech's partner Teva initiates a laqui... [Published GlobeNewswire: Advertising News - Aug 14 2014]
The Launch of Five Immunomodulatory Therapies f... [Published PR Newswire: General Business - Aug 07 2014]
Active Biotech AB Interim report January-June 2014 [Published GlobeNewswire: Acquisitions News - Aug 07 2014]
Active Biotech AB Interim report January-June 2014 [Published GlobeNewswire: Acquisitions News - Aug 07 2014]
Cantargia gears up with new CEO and substantial... [Published CisionWire - English - Jun 17 2014]
Active Biotech presents data on paquinimod at E... [Published GlobeNewswire: Acquisitions News - Jun 11 2014]
Active Biotech presents data on paquinimod at E... [Published GlobeNewswire: Acquisitions News - Jun 11 2014]
Active Biotech to Present at Jefferies 2014 Hea... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
Active Biotech to Present at Jefferies 2014 Hea... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
EMA's CHMP rejects approval of multiple scleros... [Published PBR - News - May 26 2014]
Teva and Active Biotech to continue with the de... [Published GlobeNewswire: Acquisitions News - May 23 2014]
Teva and Active Biotech to Continue with the De... [Published Business Wire Science: Science News - May 23 2014]
Teva and Active Biotech to Continue with the De... [Published Business Wire Health News - May 23 2014]
Annual General Meeting of Active Biotech AB [Published GlobeNewswire: Acquisitions News - May 16 2014]
Annual General Meeting of Active Biotech AB [Published GlobeNewswire: Acquisitions News - May 16 2014]
Active Biotech AB Interim report January - Marc... [Published GlobeNewswire: Acquisitions News - Apr 24 2014]
Active Biotech AB Interim report January - Marc... [Published GlobeNewswire: Acquisitions News - Apr 24 2014]
Active Biotech schedules AGM [Published TrustNet - Apr 14 2014]
Active Biotech - Notice of Annual General Meeti... [Published GlobeNewswire: Advertising News - Apr 14 2014]
Active Biotech - Notice of Annual General Meeti... [Published GlobeNewswire: Advertising News - Apr 14 2014]
Annual Report 2013 Active Biotech AB publ [Published BioPortfolio - Apr 07 2014]
Annual Report 2013 Active Biotech AB (publ) [Published GlobeNewswire: Advertising News - Apr 07 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Teva Presents New Clinical Safety Data in RRMS ... [Published Business Wire Health News - Sep 12 2014]
JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting ...
The Launch of Five Immunomodulatory Therapies f... [Published PR Newswire: General Business - Aug 07 2014]
BURLINGTON, Mass., Aug. 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, ...
Cantargia gears up with new CEO and substantial... [Published CisionWire - English - Jun 17 2014]
Cantargia, a private biopharmaceutical company developing therapeutics for the treatment of leukemia, announces that Dr. Göran Forsberg will take over the CEO position Furthermore, the company has decided to issue new shares corresponding to 20 MSEK.Cantargia ...
EMA's CHMP rejects approval of multiple scleros... [Published PBR - News - May 26 2014]
European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rejected the development of Nerventra (Laquinimod) for the treatment of relapsing-remitting multiple sclerosis (RRMS) by Israel-based Teva Pharmaceutical and Swedish ...
Teva and Active Biotech to Continue with the De... [Published Business Wire Science: Science News - May 23 2014]
JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) announced today that the Committee for Medicinal Products for Human Use (CHMP) confirmed its January 23, 2014 opinion ...
1 2

Press Releases

sort by: Date | Relevance
Teva Presents New Clinical Safety Data in RRMS ... [Published GlobeNewswire: Acquisitions News - Sep 12 2014]
Active Biotech's partner Teva initiates a laqui... [Published GlobeNewswire: Advertising News - Aug 14 2014]
Active Biotech's partner Teva initiates a laqui... [Published GlobeNewswire: Advertising News - Aug 14 2014]
Active Biotech AB Interim report January-June 2014 [Published GlobeNewswire: Acquisitions News - Aug 07 2014]
Active Biotech AB Interim report January-June 2014 [Published GlobeNewswire: Acquisitions News - Aug 07 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.